NIMGenetics

NIMGenetics is a Spanish biotechnology and healthcare company, founded in 2007, that operates as an analytical diagnostic center with a genetics unit authorized by the Health Department of the Community of Madrid. The company's accredited scientific and medical team is specialized in high-resolution genomic systems, aiming to provide reliable and precise clinical diagnosis. One of NIMGenetics' main objectives is to efficiently provide medical professionals with the latest scientific advances in genomic tools, such as CGH arrays, to enhance healthcare in terms of prevention, prognostic characterization, and diagnostic reliability. Additionally, the company offers personalized services to researchers and research institutions, including the design and selection of suitable platforms and comprehensive bioinformatic analysis. Since 2008, NIMGenetics has been backed by the CDTI, enhancing its innovation capabilities. The company has developed and validated various genomic analysis platforms with clinical applicability, such as KaryoNIM®, which facilitates the identification of DNA copy number alterations with phenotypic repercussions. In 2009, NIMGenetics was accredited by the Health Department of the Community of Madrid as an Analytical Diagnostic Center with a Genetics Unit. Currently, over 50 diagnostic centers, clinics, and hospitals utilize NIMGenetics' services. In May 2017, the company received a significant €7.00M Venture Round investment led by Apposite Capital. This investment has further bolstered NIMGenetics' position in the biotechnology and healthcare space, potentially paving the way for continued growth and innovation in the company's offerings.